Executive Chairman Raymond F. Akers Jr., Ph.D, to present at:
Rodman & Renshaw 16th Annual Global Investment Conference; and Aegis Capital Corporation 2014 Healthcare & Technology Conference
THOROFARE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company") a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, will present this week at the Rodman & Renshaw 16th Annual Global Investment Conference and the Aegis Capital Corporation 2014 Healthcare and Technology Conference.
The Rodman & Renshaw 16th Annual Global Investment Conference is being held at the New York Palace Hotel, New York City. The Company is scheduled to make its presentation on Wednesday, September 10 at 12:05 PM in Kennedy I Salon (4th floor); and is conducting one-on-one meetings throughout the day. For more information visit: http://www.rodm.com/.
The Aegis Capital Corp. 2014 Healthcare and Technology Conference is being held at the Encore and Wynn Las Vegas. The Company is scheduled to make its presentation on Friday, September 12 at 09:00 AM in Chopin 2; and is conducting one-on-one meetings throughout the day. For more information visit: www.meetmax.com/aegis14.html.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.